Trial reportAntimicrobial agents and chemotherapy2002
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.
Trial report in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00388167 (PROCAS), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 255 citations in OpenAlex.
- Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.The Cochrane database of systematic reviews · 2010Pooled it
- Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.Pharmaceutical research · 2015Trial
- Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.Antimicrobial agents and chemotherapy · 2013Trial
- Phase II dose escalation study of caspofungin for invasive Aspergillosis.Antimicrobial agents and chemotherapy · 2011Trial
- Pharmacokinetics and safety of caspofungin in older infants and toddlers.Antimicrobial agents and chemotherapy · 2009Trial
- Potential for interactions between caspofungin and nelfinavir or rifampin.Antimicrobial agents and chemotherapy · 2004Trial
- Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.Antimicrobial agents and chemotherapy · 2004Trial
- Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.Clinical pharmacokinetics · 2024Review
- Comparative Efficacy of Antifungal Agents Used in the Treatment of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis.Journal of fungi (Basel, Switzerland) · 2021Review
- Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety.Cardiovascular toxicology · 2021Article
- Tissue penetration of antifungal agents.Clinical microbiology reviews · 2014Review
- The use of antifungal therapy in neonatal intensive care.Clinics in perinatology · 2012Review
- Fungal infections: their diagnosis and treatment in transplant recipients.International journal of hepatology · 2012Article
- Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.Clinical medicine insights. Pediatrics · 2012Article
- Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.Antimicrobial agents and chemotherapy · 2011Article
- Review
- Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT.Bone marrow transplantation · 2010Article
- Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.Antimicrobial agents and chemotherapy · 2010Article
- Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.HIV/AIDS (Auckland, N.Z.) · 2010Article
- Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caspofungin is an antifungal agent of the novel echinocandin class. We investigated its efficacy, safety, and tolerability as therapy for oropharyngeal and/or esophageal candidiasis in a phase II dose-ranging study. Patients were randomized in a double-blind manner to receive either caspofungin acetate (35, 50, or 70 mg) or amphotericin B (0.5 mg/kg of body weight) intravenously once daily for 7 to 14 days. A favorable response required both complete resolution of symptoms and quantifiable improvement of mucosal lesions 3 to 4 days after discontinuation of study drug. Efficacy was assessed using a modified intent-to-treat analysis. No hypothesis testing of efficacy was planned or performed. Of 140 enrolled patients, 63% had esophageal involvement and 98% were infected with the human immunodeficiency virus (HIV) (median CD4 count, 30/mm(3)). A modestly higher proportion of patients in each of the caspofungin groups (74 to 91%) achieved favorable responses compared to amphotericin B recipients (63%), but there was considerable overlap in the 95% confidence intervals surrounding these point estimates. Similar trends were found in the subgroups with esophageal involvement, a history of fluconazole failure, and CD4 counts of < or =50/mm(3). A smaller proportion of patients receiving any dose of caspofungin experienced drug-related adverse events compared to patients given standard doses of conventional amphotericin B (P < 0.01). Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.